Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder that affects the blood vessels. A person with HHT may have blood vessels that have not developed properly and may have no ...

HHT is an autosomal dominant bleeding condition, meaning a person only needs to inherit one copy of the gene variation to develop symptoms. As such, there is a 50% risk of someone inheriting the ...

People with HHT have a near-typical life expectancy as long as they follow their treatment plan and undergo regular screening for complications. Hereditary hemorrhagic telangiectasia (HHT) is a ...

The motivation for the newly reported trial was a single patient. About 15 years ago McCrae saw the patient, then in his 50s, with symptoms of HHT, a disorder about which little information was ...

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant vascular dysplasia characterized by telangiectases and arteriovenous malformations. Three causative genes are known: ENG (HHT-1 ...

Hereditary hemorrhagic telangiectasia (HHT) (also known as the Osler–Weber–Rendu syndrome) is an inherited vascular dysplasia whose main features are mucocutaneous telangiectasias, epistaxis ...

A total of 80 HHT patients across the USA, Canada and Europe will be randomised in a double-blind, controlled trial comparing two doses of VAD044 to placebo.

To describe clinical presentations of hereditary hemorrhagic telangiectasia (HHT) patients in Japan. There were 80 patients (40 men and 40 women, age 2–78, mean 39.4 years old), who were either ...

Trial delivers positive results in first ever industry-led clinical trial in Hereditary Haemorrhagic Telangiectasia (HHT) VAD044 showed favourable safety and tolerability, together with ...

Diagonal is advancing its lead program to treat the underlying cause of hereditary hemorrhagic telangiectasia (HHT)WATERTOWN, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a ...

The mean difference in the changes in the HHT-specific quality-of-life score between the groups was −1.4 points (95% CI, −2.6 to −0.3).